A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04691804
Phase: Phase 3
Trial Summary: To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Jiangsu HengRui Medicine Co., Ltd.
Acronym:

Pin It on Pinterest